Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEOLVP)

Drug Name

NI-0401 Drug Info

Synonyms

Anti-CD3 antibody, NovImmune/Merck Serono

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Regulatory protein unspecific (RGP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teplizumab	DMZ3P6C	Type-1 diabetes	5A10	Approved	[3]
Visilizumab	DMXYM1H	Graft-versus-host disease	4B24	Phase 3	[4]
MEDI-500	DMT3B4G	Bone marrow transplantation	QB63.6	Terminated	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Regulatory protein unspecific (RGP)	TTBMAOZ	NOUNIPROTAC	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00805909) NI-0401 in Patients With Acute Renal Allograft Rejection. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of NovImmune.
3	Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40(10):2891-901.
4	Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.
5	T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant. 1996 Dec;10(6 Pt 2):607-13.